Navigation Links
Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division

MISSISSAUGA, Ontario, BRIDGEWATER, New Jersey and BIRMINGHAM, Alabama, Jan. 10 /PRNewswire/ -- CANTOX HEALTH SCIENCES INC. and CANTOX US INC., a leading international scientific and regulatory consulting firm with specialized expertise in the areas of Pharmaceutical & Healthcare, Food & Nutrition, Chemicals and Agriculture, Biotech & Consumer Products announces the launch of Ashuren Health Sciences as the new name for their Pharmaceutical & Healthcare Division.

For the past 20 years, Cantox has been helping clients resolve complex scientific and toxicology issues, develop scientific and strategic regulatory plans, and facilitating timely regulatory global approvals. Cantox has been optimizing success and minimizing client risk through broad expertise and knowledge.

"The decision to rename the Pharmaceutical & Healthcare Division 'ASHUREN Health Sciences' was taken in order to more accurately represent our expanding global client base and to reflect our diverse international regulatory agency interactions," said Lindsay N. Donald, Vice President of Ashuren Pharmaceutical & Healthcare. "We have been assisting clients with their toxicology and drug development issues in Europe, North America, Asia and Australia."

"In order to rapidly and cost effectively move drugs through development it is imperative to anticipate scientific and regulatory issues ahead of time," commented Anna Metcalfe, Vice President of Regulatory Affairs for Ashuren. "This is where the experience of Ashuren's scientific and regulatory affairs consultants can really aid our pharmaceutical and biotech clients."

About Ashuren

Ashuren Health Sciences is a focused team of scientific and regulatory consultants that can help develop strategies, provide expert advice on all aspects of product development programs, and provide advice on a wide variety of toxicology and regulatory issues for pharmaceutical and related products. With diverse and in-depth experience in pharmaceutical development, our resourceful and innovative team consisting of board-certified toxicologists, regulatory affairs specialists and scientific writers address client's needs and accelerate their development programs. For more information, please visit:

SOURCE Ashuren Health Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):